1. Scrip
  2. >>Business
  3. >>Deals

Private Equity Eyes Pharma As Vectura Gets Snapped Up By Carlyle

UK Firm Bought Out For Nearly $1.4bn

 
• By Kevin Grogan

Cash-rich private equity firms are eyeing opportunities in healthcare, especially among listed companies with sluggish share prices. The Carlyle Group could be getting a bargain if it seals a deal for the Chippenham-based inhalation specialist.

Hand man doing finances and calculate on desk about cost at home office.
Healthcare acquisitions add up for private equity • Source: Archive

Vectura Group plc, a stalwart of the UK biotech sector, has agreed to be acquired by The Carlyle Group in a deal worth £958m ($1.36bn), the latest example of private equity firm's increased interest in the healthcare space.

The board at the Chippenham-based inhalation specialist which is listed on the London Stock Exchange, has recommended a £1.55 per share offer which represents a 27% premium on Vectura's closing price on May 25

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Pharma Predicts Modest Impact From Tariffs, But It Depends On What Comes Next

 
• By Jessica Merrill

Drugmakers aren’t expecting a big financial hit from tariffs for now, but a report commissioned by PhRMA suggests the cost of pharma-sector tariffs could be steep.

OPPI’s Matai On Section 3(d) Of India’s Patent Regulations: Now’s The Time To Open Up

 
• By Anju Ghangurde

Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India’s patent regulations and innovator firms' experience of the Bolar provision. There’s also a "compelling reason" to consider regulatory data protection, he claims.

In Brief: Sanofi Gains €10bn From Opella Sale

 
• By Sushmita Panda

Sanofi sold a 50% stake in consumer health unit Opella for €10bn, backing its shift to prescription drugs and funding a €5bn buyback.